semaglutide cardiovascular outcomes 2025 news today semaglutide reduces the risk of major adverse cardiovascular events - Oralsemaglutidein type 2 diabetes semaglutide reduced myocardial infarction and stroke risk Semaglutide Cardiovascular Outcomes: Pivotal 2025 News and Emerging Data

New oralsemaglutide The year 2025 has proven to be a landmark period for understanding the cardiovascular benefits of semaglutide, a widely recognized GLP-1 receptor agonist. Emerging research and regulatory updates continue to solidify its role in reducing major adverse cardiovascular events (MACE), offering new hope for patients with overweight, obesity, type 2 diabetes, and established cardiovascular disease. This comprehensive overview delves into the latest news, key trial findings, and the evolving understanding of how semaglutide impacts heart health.

A significant contributor to this evolving narrative is the SELECT trial, a pivotal study that has demonstrated semaglutide reduced major adverse cardiovascular events in individuals with overweight or obesity. This finding is crucial, as it extends the known benefits of semaglutide beyond glycemic control2025年9月19日—Additional results from REACH demonstrate that once-weeklysemaglutidewas associated with a 25% risk reduction of heart attack, stroke, .... Further analysis from these trials highlights that the cardiovascular benefit was not related to the amount of weight that patients lost while taking semaglutide, suggesting intrinsic mechanisms at play beyond weight reduction.SOUL Findings Highlight Cardiovascular Benefits Beyond ... This challenges previous assumptions and opens new avenues for research into the drug's direct effects on the cardiovascular systemCardiovascular benefits of semaglutide: a systematic review ....

Recent analyses presented at major cardiology conferences and published in peer-reviewed journals underscore these findings. For instance, results from the REACH Study demonstrated that once-weekly semaglutide was associated with a 25% risk reduction of heart attack and stroke. Similarly, real-world data has indicated that Wegovy (a higher-dose formulation of semaglutide) reduced the risk of heart attack, stroke, or death by 57% compared to tirzepatide in specific patient populations.Novo Nordisk REACH Study Shows Ozempic Reduces ... These data points reinforce the robust protective effects observed in clinical trials.

The efficacy of oral semaglutide has also been a major focus in 2025.2025年9月19日—Additional results from REACH demonstrate that once-weeklysemaglutidewas associated with a 25% risk reduction of heart attack, stroke, ... The SOUL trial has shown significant positive cardiovascular outcomes with this formulation.MHRA Backs Higher-Dose Wegovy After 20% Weight Loss Specifically, oral semaglutide has improved each of the composite measures, including death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction. Further findings from the SOUL trial indicate that oral semaglutide reduced myocardial infarction (HR 02026年1月9日—The SELECT phase 3 trial sawsemaglutideoutperform placebo in reducing the risk of major adversecardiovascularevents in patients with ....81) and stroke (HR 0STRIDE and SOUL: Semaglutide Improves PAD Outcomes.84) when compared to sitagliptin, with additional data showing oral semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular diseaseACC 2025: Oral Semaglutide Reduces Cardiovascular .... These results confirm that oral semaglutide improves CV outcomes in patients with type 2 diabetes and known CV disease, offering a convenient alternative to injectable forms.作者：J Wise·2025—The new study found that the 20% reduction in myocardial infarction, stroke, and other majorcardiacevents was similar regardless of ... Presentations at key scientific gatherings like the AHA and ACC in 2025 have further highlighted that Oral Semaglutide Reduces Cardiovascular Events by 14% at Four Years, providing valuable insights into its long-term impactReal-world data shows Novo Nordisk's semaglutide ....

Beyond the SELECT and SOUL trials, a systematic review and meta-analysis have confirmed that semaglutide reduces the risk of major adverse cardiovascular events, including cardiac events and cardiovascular death.2025年9月19日—From EASD2025: Oralsemaglutidereduces the risk of MACE in patients with type 2 diabetes and increasedcardiovascularrisk. This comprehensive evidence base is critical for informing clinical practice and patient care. The World Health Organization (WHO) has also taken note, adding GLP-1 therapies to its Essential Medicines List in September 2025 for managing type 2 diabetes in high-risk groups, reflecting the growing recognition of their broader health benefits.

While weight loss is a notable effect of semaglutide, research suggests its cardiovascular benefits are more multifaceted.2025年11月18日—In the expanded population,semaglutide reduced myocardial infarction and stroke risk, with an HR of 0.82, compared with sitagliptin. This ... Studies indicate that the reduction in cardiac events associated with semaglutide is significant, with some trials reporting a 20% decreased risk of experiencing non-fatal heart attacks, non-fatal strokes, or death. This is particularly important for patients where cardiovascular outcomes are as critical as glycemic control.Diabetes drugs semaglutide and tirzepatide show real ...

The comparative effectiveness of semaglutide and tirzepatide in reducing cardiovascular events is also an active area of research. While both drugs have shown efficacy in reducing MACE, head-to-head comparisons are ongoing. Preliminary data suggests that in certain patient groups, semaglutide and tirzepatide reduced major adverse cardiovascular events. However, the specific nuances of their comparative cardiovascular profiles continue to be elucidated.Cardiovascular benefits of semaglutide: a systematic review ...

Looking ahead, ongoing research and new analyses are expected to provide even deeper insights into the mechanisms and broad applications of semaglutide.SOUL Findings Highlight Cardiovascular Benefits Beyond ... Novo Nordisk is set to present new data on the drug's impact on 'food noise,' body composition, and cardiovascular benefits, further enriching our understanding of its therapeutic potential. The availability of both injectable and oral formulations, coupled with robust clinical trial evidence, positions semaglutide as a cornerstone therapy for managing cardiovascular risk in diverse patient populations. The cumulative evidence from 2025 trials strongly supports the role of semaglutide in improving cardiovascular health, offering a vital tool in the fight against heart disease and stroke.2025年5月18日—The researchers found that participants who receivedsemaglutidehad a 20% decreased risk of experiencing non-fatal heart attacks, non-fatal strokes, or death ...